pyrroles has been researched along with Epithelial Neoplasms in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Antonarelli, G; Catania, C; Conforti, F; Corti, C; Curigliano, G; De Pas, T; Lo Russo, G; Manglaviti, S; Perrino, M; Salvini, P; Varano, GM; Zucali, PA | 1 |
| Brady, W; Brown, J; Chan, JK; Gershenson, DM; Kim, JH; Monk, BJ; Rose, PG; Secord, AA; Shahin, MS; Walker, JL | 1 |
| Gao, L; Gao, Y; Li, J; Shan, N; Wang, Y; Xu, F; Yi, Z; Yu, X; Zhao, C | 1 |
| Besse, B; Dansin, E; Dubos, C; Girard, N; Greillier, L; Lindsay, CR; Mazieres, J; Pichon, E; Remon, J | 1 |
| Alsina-Sanchis, E; Casanovas, O; Figueras, A; Graupera, M; Lahiguera, Á; Vidal, A; Villanueva, A; Viñals, F | 1 |
| Amaravadi, RK; Anglesio, MS; DeVorkin, L; Hattersley, M; Huntsman, DG; Kim, P; Levi, SM; Lum, JJ; Ries, J; Spowart, J; Tinker, AV; Winkler, JD | 1 |
| Bajorin, DF; Boyle, MG; Flaherty, AM; Gallagher, DJ; Gerst, SR; Ishill, N; Milowsky, MI; Regazzi, A; Riches, J; Trout, A | 1 |
| Biagi, JJ; Chalchal, HI; Eisenhauer, EA; Ellard, SL; Grimshaw, R; Hirte, H; Ivy, SP; Lee, U; Oza, AM; Sederias, J | 1 |
| Colon-Otero, G; Copland, JA; Kennedy, GT; Kennedy, WP; Marlow, LA; Santoso, JT; Vishnu, P; Wu, KJ | 1 |
| Giaccone, G; Killian, KJ; Lee, C; Lee, HS; Luo, J; Meltzer, PS; Petrini, I; Roncalli, M; Santoro, A; Steinberg, SM; Tsokos, M; Wang, Y; Zucali, PA | 1 |
| Bodis, S; Hofstetter, B; Pruschy, M; Riesterer, O; Tenzer, A; Vuong, V; Zingg, D | 1 |
3 trial(s) available for pyrroles and Epithelial Neoplasms
| Article | Year |
|---|---|
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Ovarian Epithelial; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pyrroles; Sunitinib; Young Adult | 2018 |
Phase II study of sunitinib in patients with metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Pyrroles; Sunitinib; Survival Analysis; Urinary Bladder Neoplasms; Urothelium | 2010 |
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CA-125 Antigen; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrroles; Recurrence; Sunitinib; Survival Analysis | 2011 |
8 other study(ies) available for pyrroles and Epithelial Neoplasms
| Article | Year |
|---|---|
Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.
Topics: Humans; Indoles; Neoplasms, Glandular and Epithelial; Platinum; Pyrroles; Retrospective Studies; Sunitinib; Thymoma; Thymus Neoplasms; Treatment Outcome | 2022 |
LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Mice, Inbred ICR; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad2 Protein; Time Factors; Transforming Growth Factor beta; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Sunitinib; Thymoma; Thymus Neoplasms; Treatment Outcome; Young Adult | 2016 |
The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Ovarian Epithelial; Cell Proliferation; Female; Heterografts; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pyrazoles; Pyrroles; Random Allocation; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Transforming Growth Factor beta | 2016 |
Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma.
Topics: Adenocarcinoma, Clear Cell; Aminoquinolines; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; Indoles; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyamines; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2017 |
RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Growth Processes; Cell Line, Tumor; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Synergism; Epothilones; Female; Humans; Indoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pyrroles; rhoB GTP-Binding Protein; Sunitinib; Up-Regulation | 2012 |
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Aniline Compounds; Animals; Apoptosis Regulatory Proteins; Autophagy; bcl-X Protein; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; DNA Copy Number Variations; Female; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; RNA Interference; RNA, Small Interfering; Sorafenib; Sulfonamides; Thymus Neoplasms; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2012 |
Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?
Topics: Cell Survival; Combined Modality Therapy; Down-Regulation; Endothelial Cells; Enzyme Inhibitors; ErbB Receptors; Neoplasm Proteins; Neoplasms, Glandular and Epithelial; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Pyrroles; Radiation-Sensitizing Agents; Receptors, Vascular Endothelial Growth Factor; Staurosporine | 2004 |